clinicaltestingpic

AKESOgen launches Clinical Oncology Molecular Cytogenomics Microarray Test

Atlanta, GA – 1st April, 2014— Personalized medicine and genomics company AKESOgen today announced that its CLIA-compliant laboratory has launched a new clinically validated cytogenomics microarray test. The test measures Copy Number Alterations (CNAs) across the genome utilizing Illumina’s CytoSNP 850K beadarray. The assay is validated across a wide spectrum of cancers e.g. solid tumors including breast, lung, brain and liquid tumors such as leukemias and lymphomas. It is also validated using a wide variety of starting materials including FFPE tissue, blood and bone marrow.

“We are delighted to launch our cytogenomic array test as it has enormous clinical utility – for prognosis and clinical work up. We believe we are the only commercial laboratory in the USA running this test on the Illumina platform utilizing FFPE tissue.” said Mark Bouzyk, CSO of AKESOgen.

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Share this FacebooktwitterredditlinkedinmailFacebooktwitterredditlinkedinmail
millvet

Million Veteran Program: A Partnership with Veterans

AKESOgen and the VA Million Veteran Program to collaborate on genotyping 105,000 veterans
 

Norcross, GA, USA – March 5th 2014 – AKESOgen announced today that it has been awarded a $7.5M contract by the U.S. Department of Veterans Affairs (VA) for genotyping samples from U.S. veterans as part of the Million Veteran Program (MVP). This award covers the genotyping of 105,000 veterans in the first year of a five year contract.

“The VA’s Million Veteran Program is one of the largest genetic initiatives ever undertaken in the US and its visionary genomics and genetics approach will provide new insights about how genes affect health. The goal is to improve healthcare for veterans by understanding the genetic basis of many common conditions. The data will ultimately be beneficial to the healthcare of all veterans and of the wider community. We are delighted to have been selected by the VA for this unique endeavor and we will provide genetic data of the highest quality to the VA.” said Bob Boisjoli, CEO of AKESOgen. To fulfill the VA contract, AKESOgen will utilize a custom designed array based genotyping solution from Affymetrix, Inc.

“We are honored to be part of the MVP project by providing our Axiom Genotyping Solution to support the VA’s goal of building one of the largest genetic databases in order to improve healthcare for our veterans,” commented Dr. Frank Witney, President and CEO of Affymetrix.

AKESOgen provides genomics services for the research and development market, including biobanking, DNA/RNA extraction, and genetic technologies. Founded in 2010, the company services the clinical, pharmaceutical, biotechnology, academic, and government sectors.

To learn more about AKESOgen, please visit www.akesogen.com.

About AKESOgen, Inc.
AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.

About the VA Million Veteran Program

Launched in 2011, MVP is a landmark research effort aimed at better understanding how genes affect health. Up to a million Veterans are expected to enroll in the VA study over the next 5-6 years. Data and genetic samples collected through the study are stored securely and made available for studies by authorized researchers, with stringent safeguards in place to protect Veterans’ private health information. MVP is now enrolling at over 50 VA medical centers nationwide. The VA’s central bio-repository is equipped with a state-of-the-art robotic system for DNA extraction and storage and is currently being expanded to support up to 4 million samples. With more than 240,000 enrollees to date, MVP already far exceeds the enrollment numbers of any single VA study or research program in the past. MVP provides researchers with a rich resource of genetic, health, lifestyle, and military-exposure data collected from questionnaires, medical records, and genetic analyses. By combining this information into a single database, MVP promises to advance knowledge about the complex links between genes and health. Veterans’ privacy and confidentiality are top priorities in MVP, as in all VA research. For more information about MVP, visit www.research.va.gov/MVP

Contact details
AKESOgen, Inc.
Mark Bouzyk, PhD, Chief Scientific Officer
404 771 8667
mbouzyk@akesogen.com

– See more at: http://www.akesogen.com/?page=newsandevents-pressreleases#sthash.tnSddBze.dpuf

Share this FacebooktwitterredditlinkedinmailFacebooktwitterredditlinkedinmail
athena

AKESOgen to Analyze Specimens in Breast Cancer Research

Edith Sanford Breast Cancer, Athena Breast Health Network Team for Breast Cancer Research; Akesogen to Perform Analysis

Genetic analysis of 3,000 women could identify cancer risk
 

Newswise – (Sioux Falls, SD/San Francisco, CA) – Three-thousand bio specimens from women will be analyzed as part of the ongoing collaboration between Edith Sanford Breast Cancer and Athena Breast Health Network to determine whether certain genetic variants could be indicators of breast cancer, officials from both organizations announced today.

The effort aims to gather information that will impact prevention strategies and more precisely identify risk levels of developing breast cancer.

As part of the study, 1,500 women at elevated risk and 1,500 women at average risk for breast cancer will be genotyped.

“We believe this to be one of the largest groups of women to ever be studied to determine breast cancer risk levels,” said Gene Hoyme, MD, president of Sanford Research. “If an elevated risk is identified, care teams can improve the likelihood of healthier lifestyle changes and implement preventative treatments when appropriate.”

In November, Edith Sanford Breast Cancer and Athena Breast Health Network announced a partnership in which Sanford Health became a clinical partner with the Athena Breast Health Network, positioning the health system to begin providing patients with a comprehensive breast cancer risk assessment at the time of mammography screening. Additionally, the program will offer patients the opportunity to participate in research aimed at gaining a better understanding of breast cancer and its risk factors, ultimately raising the standard of care for women everywhere.

To analyze each sample from the 3,000 women, AKESOgen, an Atlanta-based biomarker and genetics company selected by Edith Sanford and Athena, will utilize Oncochip technology.

“The Oncochip is a uniquely designed genetic analysis tool that uses Illumina’s beadarray technology. It will allow us to provide genetic data of the highest quality to the collaboration. The data will benefit both the participants and the breast cancer research community,” said Mark Bouzyk, PhD, chief scientific officer of AKESOgen.

Data gathered and studied by Edith Sanford and Athena could positively influence the risk-assessment tool and care plans.

“The addition of the genetic variants risk assessment allows us to deliver a new level of personalized medicine and gain a better understanding an individual’s risk, thus putting our collaboration at the forefront of modern medicine,” said Laura van `t Veer, PhD, Director of Applied Genomics at the University of California, San Francisco and an Athena spokesperson.

Athena Breast Health Network is a collaboration among the five University of California medical centers. Edith Sanford Breast Cancer is its first partner outside of California and was selected because of its expertise in breast cancer genomics and its ability to integrate the risk assessment into patient care.

About Sanford Health and Edith Sanford Breast Cancer Sanford Health is the largest rural nonprofit health care system in the nation with locations in 126 communities, in nine states. In addition, this dynamic integrated health system is now developing international clinics in Ghana, Israel and Mexico. Sanford Health has more than 26,000 employees, and includes 39 hospitals, 140 clinic locations and 1,360 physicians in 81 specialty areas of medicine. In 2011, Sanford Health announced the launch of the Edith Sanford Breast Cancer Initiative, a bold new endeavor to end breast cancer, comprised of state-of-the-art patient care, genomic research and national fundraising through the Edith Sanford Breast Cancer Foundation. For more information, visit sanfordhealth.org or edithsanford.org.

About Athena Breast Care Network The Athena Breast Health Network (Athena) is a unique collaboration among the five University of California (UC) medical/cancer centers (UC Davis, UC Irvine, UCLA, UC San Diego and UCSF), the Graduate School of Public Health at UC Berkeley, and many other public and private partners. The Network takes a transdisciplinary approach by design, and its participants work together across fields including: epidemiology, genetics, molecular biology, psychology and social and behavioral sciences, primary care, radiology, pathology, oncology, surgery and health services research. Also included are clinical staff and genetic counselors, health information technology professionals, health care administrators, and importantly, patient advocates.

Athena is integrating clinical care and research in order to revolutionize the delivery of breast care. By standardizing the collection of data from both patients and physicians, integrating molecular profiling at the time of breast cancer diagnosis, and creating an unparalleled biospecimen repository, Athena will enable personalized care informed by science and will fuel continuous improvement in treatment options and outcomes.

Key components of Athena include:

  • Identifying women at high risk for breast cancer who will be offered prevention services and decision support.
  • A comprehensive informatics strategy that includes tools to collect, analyze, and distribute clinical and research data in real time.
  • Web-based decision tools for patients and providers to translate clinical evidence into actionable treatment options – allowing physicians to tailor treatment to biology, patient preference and clinical performance.
  • A data and biospecimen repository to support large-scale, longitudinal studies that will enable tailored prevention and treatment strategies.

 

Underpinning these goals is a culture that supports continuous improvement, as well as a commitment by Athena clinicians and researchers across California to share data. With this unique collaboration, Athena aims to change the options for patients today and create a better future for all women at risk of developing breast cancer.

UC Disclaimer The information stated above was prepared by Sanford Health and reflects solely the opinion of the health system. Nothing in this statement shall be construed to imply any support or endorsement of Sanford, or any of its products, by The Regents of the University of California, its officers, agents and employees.

About AKESOgen, Inc. AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.

– See more at: http://www.akesogen.com/?page=pr-2014-03-04#sthash.PKLo4gfY.dpuf

Share this FacebooktwitterredditlinkedinmailFacebooktwitterredditlinkedinmail

AKESOgen honored by Gwinnett Chamber of Commerce

Gwinnett Businesses Honored During

Annual New Company Reception

Partnership Gwinnett celebrates job creation, investment in County

 

(GWINNETT- METRO ATLANTA) February 21, 2014 – Partnership Gwinnett and Gwinnett Chamber Economic Development joined more than 70 business and community leaders for its annual New Company Reception last night. The event, designed to celebrate the County’s relocated or expanded businesses, recognized 16 Gwinnett companies for their growth, success, and investment in the County during 2013.

“We are proud of our proactive efforts to build and support economic development initiatives throughout the County. A result of this work is the success stories of these growing companies,” commented Gwinnett County Board of Commission Chairman Charlotte Nash, who also attended the event. “We welcome each of them to Gwinnett County and celebrate their contributions to our business community.”

Attendees included representatives from 4P Therapeutics, AKESOgen, Eagle Rock Distributing Company, Image Manufacturing Group, Lapp Group, NexxLinx, Perfetta, SolarMax, The Dennis Group, LLC, UPS Supply Chain Solutions, VetConnexx, and xpedx. The reception provided a platform for the companies to share reasons for their decision to expand within or relocate to the metro Atlanta community.

Dr. Mark Bouzyk, Chief Scientific Officer for AKESOgen, Inc., shared, “The County’s location in the center of Georgia’s Innovation Crescent, along with its close proximity to top-ranked education institutions, were deciding factors in our decision to remain and grow in the community. Our expanded Gwinnett location will allow us to develop new products, expand our capabilities, and reach new markets.” A genomics and biorepository services company, AKESOgen announced its expansion into a nearly 14,000-square-foot facility in December, and plans to add up to ten employees during 2014.

New and expanding small businesses and startup companies were also in attendance, including the 2013 Amazing Entrepreneur winner, Palmetto Grant Consulting; 2013 Amazing Entrepreneur finalist, Flairtab; and coworking support services, NEX Labs, Inc. and the Work Spot.

“The numerous resources and support services offered throughout Gwinnett County proved invaluable during the beginning stages of our business development. We are proud to be a part of a community that recognizes the important role small businesses and entrepreurs play in economic stability and success,” commented Susan Bacon, Founder and President of Palmetto Grant Consulting.

The County’s community and economic development initiative, Partnership Gwinnett, was launched in 2007 to recruit, retain, and attract business to the community. In 2013, the initiative assisted in 22 relocations or expansions, facilitating 1,594 new jobs and more than $44 million in investment for Gwinnett County.

“We are pleased to recognize the contributions of these companies to Gwinnett’s economic prosperity,” stated Randy Dellinger, Gwinnett District Manager for Jackson EMC and 2014 Partnership Gwinnett Chairman. “The Partnership Gwinnett team continually works to showcase and promote Gwinnett’s many assets to new and expanding companies, and we look forward to continued success moving into the new year.”

To learn more about the efforts of the award-winning Partnership Gwinnett initiative, please visit www.partnershipgwinnett.com.

 ###

 About Partnership Gwinnett

Partnership Gwinnett is Gwinnett’s economic and community development initiative. Led by the Gwinnett Chamber and a host of public and private partners, the initiative targets the retention and expansion of existing Gwinnett businesses in addition to the development of new business in five key market segments: Information &Technology Solutions; Health Sciences & Services; Headquarters & Professional Services; Supply Chain Management; and Advanced Manufacturing. The ultimate goal is to promote comprehensive economic development, increase education and workforce excellence, and support community and leadership development for the entire Gwinnett community. For more information on Partnership Gwinnett, the internationally award-winning community and economic development initiative, please visit www.partnershipgwinnett.com.

Media Contact

Sasha Ugi | Sasha@gwinnettchamber.org | 678.584.2261

Share this FacebooktwitterredditlinkedinmailFacebooktwitterredditlinkedinmail